D H Solomon1, G W Reed2, J M Kremer3, J R Curtis4, M E Farkouh5, L R Harrold2, M C Hochberg6, P Tsao1, J D Greenberg7. 1. Brigham and Women's Hospital, Boston, Massachusetts. 2. University of Massachusetts Medical School, Worcester and the Consortium of Rheumatology Researchers of North America (CORRONA), Southborough, Massachusetts. 3. Albany Medical College and Center for Rheumatology, Albany, New York and CORRONA, Southborough, Massachusetts. 4. University of Alabama at Birmingham. 5. Mount Sinai School of Medicine, New York, New York. 6. University of Maryland School of Medicine, Baltimore. 7. New York University School of Medicine and New York University Hospital for Joint Diseases, New York, New York, and CORRONA, Southborough, Massachusetts.
Abstract
OBJECTIVE: Use of several immunomodulatory agents has been associated with reduced numbers of cardiovascular (CV) events in epidemiologic studies of rheumatoid arthritis (RA). However, it is unknown whether time-averaged disease activity in RA correlates with CV events. METHODS: We studied patients with RA whose cases were followed in a longitudinal US-based registry. Time-averaged disease activity was assessed during followup using the area under the curve of the Clinical Disease Activity Index (CDAI), a validated measure of RA disease activity. Age, sex, presence of diabetes mellitus, hypertension, or hyperlipidemia, body mass index, family history of myocardial infarction (MI), use of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs), presence of CV disease, and baseline use of an immunomodulator were assessed at baseline. Cox proportional hazards regression models were examined to determine the risk of a composite CV end point that included MI, stroke, and death from CV causes. RESULTS: A total of 24,989 patients who had been followed up for a median of 2.7 years were included in these analyses. During followup, we observed 534 confirmed CV end points, for an incidence rate of 7.8 per 1,000 person-years (95% confidence interval [95% CI] 6.7-8.9). In models adjusted for variables noted above, a 10-point reduction in the time-averaged CDAI was associated with a 21% reduction in CV risk (95% CI 13-29). These results were robust in subgroup analyses stratified by the presence of CV disease, use of corticosteroids, use of NSAIDs or selective cyclooxygenase 2 inhibitors, and change in RA treatment, as well as when restricted to events adjudicated as definite or probable. CONCLUSION: Our findings showed that reduced time-averaged disease activity in RA is associated with fewer CV events.
OBJECTIVE: Use of several immunomodulatory agents has been associated with reduced numbers of cardiovascular (CV) events in epidemiologic studies of rheumatoid arthritis (RA). However, it is unknown whether time-averaged disease activity in RA correlates with CV events. METHODS: We studied patients with RA whose cases were followed in a longitudinal US-based registry. Time-averaged disease activity was assessed during followup using the area under the curve of the Clinical Disease Activity Index (CDAI), a validated measure of RA disease activity. Age, sex, presence of diabetes mellitus, hypertension, or hyperlipidemia, body mass index, family history of myocardial infarction (MI), use of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs), presence of CV disease, and baseline use of an immunomodulator were assessed at baseline. Cox proportional hazards regression models were examined to determine the risk of a composite CV end point that included MI, stroke, and death from CV causes. RESULTS: A total of 24,989 patients who had been followed up for a median of 2.7 years were included in these analyses. During followup, we observed 534 confirmed CV end points, for an incidence rate of 7.8 per 1,000 person-years (95% confidence interval [95% CI] 6.7-8.9). In models adjusted for variables noted above, a 10-point reduction in the time-averaged CDAI was associated with a 21% reduction in CV risk (95% CI 13-29). These results were robust in subgroup analyses stratified by the presence of CV disease, use of corticosteroids, use of NSAIDs or selective cyclooxygenase 2 inhibitors, and change in RA treatment, as well as when restricted to events adjudicated as definite or probable. CONCLUSION: Our findings showed that reduced time-averaged disease activity in RA is associated with fewer CV events.
Authors: Elke E A Arts; Jaap Fransen; Alfons A den Broeder; Calin D Popa; Piet L C M van Riel Journal: Ann Rheum Dis Date: 2014-01-23 Impact factor: 19.103
Authors: Daniel H Solomon; Elizabeth W Karlson; Eric B Rimm; Carolyn C Cannuscio; Lisa A Mandl; JoAnn E Manson; Meir J Stampfer; Gary C Curhan Journal: Circulation Date: 2003-03-11 Impact factor: 29.690
Authors: E E A Arts; C Popa; A A Den Broeder; A G Semb; T Toms; G D Kitas; P L van Riel; J Fransen Journal: Ann Rheum Dis Date: 2014-01-03 Impact factor: 19.103
Authors: Inmaculada Del Rincón; Ken Williams; Michael P Stern; Gregory L Freeman; Daniel H O'Leary; Agustín Escalante Journal: Arthritis Rheum Date: 2003-07
Authors: Brendan M Everett; Aruna D Pradhan; Daniel H Solomon; Nina Paynter; Jean Macfadyen; Elaine Zaharris; Milan Gupta; Michael Clearfield; Peter Libby; Ahmed A K Hasan; Robert J Glynn; Paul M Ridker Journal: Am Heart J Date: 2013-05-03 Impact factor: 4.749
Authors: Edward L Barnes; Renee M Beery; Allison R Schulman; Ellen P McCarthy; Joshua R Korzenik; Rachel W Winter Journal: Inflamm Bowel Dis Date: 2016-09 Impact factor: 5.325
Authors: Laura Geraldino-Pardilla; Afshin Zartoshti; Ayse Bag Ozbek; Jon T Giles; Richard Weinberg; Mona Kinkhabwala; Sabahat Bokhari; Joan M Bathon Journal: Arthritis Rheumatol Date: 2017-12-01 Impact factor: 10.995